61.98

1.05% -0.66

After Hours: 62.00 0.02 +0.03%

Bridgebio Pharma Inc (BBIO)

Overview News Price History Option Chain Financials Why BBIO Down? Discussions Forecast

Bridgebio Pharma Inc stock is traded at $61.98, with a volume of 2.14M. It is down -1.05% in the last 24 hours and up +17.25% over the past month. BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Previous Close:

$62.64

Open:

$62.74

24h Volume:

2.14M

Relative Volume:

0.82

Market Cap:

$11.85B

Revenue:

$217.77M

Net Income/Loss:

$-438.86M

P/E Ratio:

-25.72

EPS:

-2.41

Net Cash Flow:

$-456.33M

1W Performance:

-2.49%

1M Performance:

+17.25%

6M Performance:

+60.69%

1Y Performance:

+143.25%

1-Day Range:

$60.79

$64.19

1-Week Range:

$60.79

$69.48

52-Week Range:

$21.72

$69.48

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name

Bridgebio Pharma Inc

Sector

Healthcare (1136)

Industry

Biotechnology (633)

Phone

(650) 391-9740

Address

3160 PORTER DR., PALO ALTO, CA

Employee

730

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

BBIO's Discussions on Twitter

Compare BBIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BBIO Bridgebio Pharma Inc	61.98	12.07B	217.77M	-438.86M	-456.33M	-2.41
VRTX Vertex Pharmaceuticals Inc	426.00	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	642.25	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	434.07	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	826.28	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	186.23	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-25	Resumed	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Jul-14-25	Initiated	Jefferies	Buy
Jul-09-25	Upgrade	Oppenheimer	Perform → Outperform
Jun-17-25	Initiated	Wolfe Research	Outperform
Mar-31-25	Initiated	Redburn Atlantic	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight
Mar-21-24	Resumed	Raymond James	Outperform
Jan-31-24	Initiated	BMO Capital Markets	Market Perform
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Jul-18-23	Downgrade	Jefferies	Buy → Hold
Apr-19-23	Initiated	Evercore ISI	Outperform
Feb-06-23	Initiated	Cowen	Outperform
Dec-27-21	Reiterated	Mizuho	Buy
Dec-27-21	Reiterated	SVB Leerink	Outperform
Sep-10-21	Upgrade	BofA Securities	Neutral → Buy
May-21-21	Initiated	UBS	Buy
Mar-22-21	Reiterated	Goldman	Buy
Feb-22-21	Resumed	JP Morgan	Overweight
Feb-09-21	Resumed	Goldman	Buy
Jan-11-21	Reiterated	H.C. Wainwright	Buy
Dec-10-20	Reiterated	H.C. Wainwright	Buy
Jun-25-20	Initiated	BofA/Merrill	Neutral
May-19-20	Initiated	BTIG Research	Buy
Apr-13-20	Initiated	H.C. Wainwright	Buy
Feb-19-20	Initiated	Mizuho	Buy
Jul-26-19	Initiated	Raymond James	Outperform
Jul-22-19	Initiated	BMO Capital Markets	Outperform
Jul-22-19	Initiated	Goldman	Buy
Jul-22-19	Initiated	JP Morgan	Overweight
Jul-22-19	Initiated	Jefferies	Buy
Jul-22-19	Initiated	Piper Jaffray	Overweight
Jul-22-19	Initiated	SVB Leerink	Outperform

View All

Bridgebio Pharma Inc Stock (BBIO) Latest News

Nov 03, 2025

Are Shares of BridgeBio Pharma Still a Bargain After 146% Rally and Clinical Trial Buzz? - Yahoo Finance

Nov 03, 2025

Mizuho Boosts Price Target on BridgeBio Pharma to $91 From $64, Keeps Outperform Rating - MarketScreener

Nov 03, 2025

Using Bollinger Bands to evaluate BridgeBio Pharma Inc.M&A Rumor & Real-Time Volume Trigger Notifications - newser.com

Nov 03, 2025

BBIO: HC Wainwright & Co. Reiterates Buy Rating with $90 PT | BB - GuruFocus

Nov 03, 2025

Real time alert setup for BridgeBio Pharma Inc. performance2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com

Nov 03, 2025

BridgeBio Pharma to Present Ten Digital Posters on Acoramidis at AHA Scientific Sessions 2025 - Quiver Quantitative

Nov 03, 2025

BBIO: HC Wainwright & Co. Reiterates Buy Rating with $90 PT | BBIO Stock News - GuruFocus

Nov 03, 2025

BridgeBio (NASDAQ: BBIO) to share 10 AHA 2025 posters on acoramidis ATTRibute-CM data - Stock Titan

Nov 03, 2025

HC Wainwright & Co. Reiterates BridgeBio Pharma (BBIO) Buy Recommendation - Nasdaq

Nov 03, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q3 2025 Earnings Call Transcript - MSN

Nov 03, 2025

What moving averages say about BridgeBio Pharma Inc.Weekly Profit Summary & Real-Time Buy Signal Notifications - newser.com

Nov 03, 2025

New York Life Investment Management LLC Makes New $548,000 Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Nov 03, 2025

Cantor Fitzgerald Issues Positive Estimate for BBIO Earnings - MarketBeat

Nov 03, 2025

What is Leerink Partnrs' Estimate for BBIO FY2025 Earnings? - MarketBeat

Nov 03, 2025

Nov 02, 2025

Can machine learning forecast BridgeBio Pharma Inc. recoveryJuly 2025 News Drivers & Smart Money Movement Alerts - newser.com

Nov 02, 2025

Nisa Investment Advisors LLC Sells 4,667 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat

Nov 02, 2025

What indicators show strength in BridgeBio Pharma Inc.July 2025 Retail & Verified Momentum Stock Watchlist - newser.com

Nov 02, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Nov 02, 2025

BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue - MSN

Nov 02, 2025

Nov 01, 2025

Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) Director Sells $13,206,742.22 in Stock - MarketBeat

Nov 01, 2025